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Bilirubin was previously considered a toxin byproduct of heme catabolism. However, a
mounting body of evidence suggests that at physiological doses, bilirubin is a powerful
antioxidant and anti-atherosclerotic agent. Recent clinical studies have shown that human
beings with genetically-induced hyperbilirubinemia (Gilbert Syndrome) are protected
against coronary heart disease. The purpose of this study was to investigate whether
administration of exogenous bilirubin to normal rats would convey similar protective effects
in an experimental model of coronary ischemia. We hypothesized that intraperitoneal
bilirubin administration 1 h before injury would decrease infarct area and preserve left
ventricular (LV) systolic function when compared to non-treated rats. Coronary ischemia
was induced by temporary (30min) ligation of the left anterior descending coronary artery
in control or bilirubin treated rats, followed by a 1-h period of reperfusion. LV function was
estimated by measurements of fractional shortening (FS) and fractional area shortening
using echocardiography. LV function decreased in both experimental groups after ischemia
and reperfusion, although in bilirubin-treated rats FS was less depressed during the period
of ischemia (18.8 vs. 25.8%, p = 0.034). Infarct size was significantly reduced in the
bilirubin treated group compared to the non-treated group (13.34 vs. 25.5%, p = 0.0067).
Based on the results of this study, bilirubin supplementation appears to provide significant
decrease in infarct size although protective effects on LV function were noted only during
the period of ischemia. This result also suggests that lipid soluble antioxidant bilirubin
prevents the oxidation of cardiolipin and decreases the infarct size in the heart during
ischemia.
Keywords: bilirubin, cardiac ischemia, ischemia reperfusion injury, myocardial infarction, infarct area, fractional
shortening, antioxidant
INTRODUCTION
Heme oxygenase 1 (HO-1), originally known as heat shock pro-
tein 32, is the sole enzyme controlling degradation of the heme
molecule, forming equimolar quantities of carbon monoxide
(CO), biliverdin (BV) and iron (Fe+2). BV is then converted
into bilirubin by the enzymatic activity of bilirubin reductase
(Maines, 1988). Initially, the HO-1 pathway and its byproducts
were perceived as steps in a metabolic pathway for catabolism
of the toxic heme molecule; however, mounting evidence sug-
gests that HO-1 is an acute phase reactant that plays a crucial
role in cytoprotection during cell stress. Upregulation of HO-
1 by administration of the enzyme substrate hemin provided
remarkable protection against ischemia-reperfusion injury in a
rat model of myocardial infarction (Masini et al., 2003). Similarly,
transgenic mice overexpressing HO-l in the heart, showed an
enhanced functional recovery during reperfusion after ischemia
compared with nontransgenic controls (Vulapalli et al., 2002).
Evidence now suggests that many of the protective effects of HO-1
are conveyed by the byproducts of heme degradation, biliru-
bin and CO, and that administration of these molecules may
provide a means of supplementing the endogenous protective
mechanisms that are already activated in various forms of car-
diovascular disease or ischemia-reperfusion injury (Clark et al.,
2000; Kato et al., 2003; Nakao et al., 2003; Adin et al., 2005;
Nakao et al., 2005, 2006). Bilirubin, in particular, has been tied
to cardiovascular disease risk, with numerous studies document-
ing that serum bilirubin levels are inversely proportional to risk
of cardiovascular disease and atherosclerosis in human beings
(Schwertner et al., 1994; Breimer et al., 1995; Hopkins et al., 1996;
Mayer, 2000; Djousse et al., 2001; Temme et al., 2001; Ollinger
et al., 2007; Ghem et al., 2010; Gul et al., 2013). While bilirubin
may have several potential mechanisms of cytoprotective action,
its primary role is as an antioxidant; bilirubin has been shown
to be the most powerful antioxidant in serum, with increasing
potency at lower oxygen concentrations (Stocker et al., 1987). At
physiologic doses of 2–20 uM, bilirubin has antinitrosative effects
(Minetti et al., 1998; Kaur et al., 2003; Kirkby and Adin, 2006)
and inhibits vascular smooth muscle proliferation (Ollinger et al.,
2005), while at higher doses, cytotoxicity can result (Kapitulnik,
2004).
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Although this clinical and experimental evidence supports the
importance of bilirubin in preventing chronic vascular disease
and atherosclerosis, there have been few investigations of the
protective effects of bilirubin in acute myocardial ischemia and
reperfusion (IR). Clinical evidence in one recent study does sug-
gest that serum bilirubin levels are inversely proportional to the
risk of complications experienced by patients with acute myocar-
dial infarction, but supplementation of bilirubin in these patients
has not been investigated (Gul et al., 2013). Based on previous
experience in manipulation of the HO-1 pathway in models of
acute organ ischemia (Bonnell et al., 2004; Adin et al., 2005;
Nakao et al., 2006; Vitek and Ostrow, 2009) and on the impor-
tance of free radicals in acute myocardial injury (Werns et al.,
1985, 1986) we suspected that pre-treatment with exogenous
bilirubin therapymay provide a practical means of reducing tissue
injury in themilieu of acute coronary IR injury that occurs during
clinical application of interventional cardiology (stenting and bal-
loon angioplasty) or administration of thrombolytic therapies to
humans with active myocardial infarction. In this study, we inves-
tigated the effects of bilirubin supplementation using a rat model
of left anterior descending coronary artery occlusion (LAD) and
acute reperfusion injury. We hypothesized that bilirubin admin-
istration would decrease infarct area and preserve left ventricular
(LV) function when compared to non-treated rats. Our eventual
goal is to apply supplemental bilirubin as a prophylactic therapy
in human beings at risk for cardiac IR injuries.
MATERIALS AND METHODS
ANIMALS
Twelve-week-old, Male Sprague Dawley rats, weighing 220–300 g,
were purchased from Harlan Sprague Dawley (Indianapolis, IN).
Animals were maintained in a temperature-controlled room and
were fed with a standard diet and water ad libitum. All procedures
were approved by The Ohio State University Institutional Animal
Care and Use Committee and were performed in accordance with
the Institute for Lab Animal Research Guide for the Care and Use
of Laboratory Animals.
BILIRUBIN STOCK SOLUTION
Bilirubin stock solutions were prepared to a final concentration of
2mM. To make the stock solution, 0.0584 g bilirubin (Bilirubin
mixed isomers B4126, Sigma-Aldrich, St Louis MO) was dis-
solved in 0.5mL 0.2 N NaOH, then total volume was increased by
addition of RPMI 1640 + 10% FBS to a total volume of 50mL.
Adjustment of pH to 7.4 was achieved by adding hydrochloric
acid. Aliquots of 2mM bilirubin in RPMI and 10% FBS were
stored at−80◦C and were protected from light until being thawed
and used for each experiment.
EXPERIMENTAL GROUPS
Male Sprague Dawley rats were randomly assigned into one of
three treatment groups. Group 1 was administered the vehicle
(PBS; n = 5), and Group 2 was administered bilirubin (10mg/kg;
IP; n = 5), 1 h before occlusion. To control for effects of anes-
thesia on cardiac function a third, sham-operated group (n = 5)
underwent anesthesia and thoracotomy, without LAD occlusion
or treatment.
SURGICAL PROCEDURE
Body weight was recorded for each animal before the procedure.
Anesthesia was induced by insufflating 5% isoflurane in 100%
oxygen (2–3min) into an induction chamber. After induction, an
injection of 0.4mL Ketamine (50mg/mL; 10mg/kg) was admin-
istered intra-peritoneally (IP) to supplement anesthesia during
the tracheostomy and to decrease the subsequent requirement for
isoflurane. A facemask was then used to deliver 100% O2 and
isoflurane (1–2%) until tracheostomy access was obtained. A ven-
tral midline cervical approach was made and tracheostomy was
performed using a16 gauge intravenous catheter. Each catheter
was secured to the skin using 3–0 silk suture, to prevent tube dis-
lodgement during the surgical procedure. After intubation, anes-
thesia was maintained with positive pressure ventilation (Harvard
Rodent Ventilator, Southnatick, MA) using isoflurane (1–2.0%)
in 100% oxygen. Oxygen flow rate was set at 0.2 L/min and rats
were ventilated at a rate of 95 cycles/min and tidal volume of
2–2.5mL. A heat lamp was used to maintain body tempera-
ture at 37 ± 1◦; temperature was monitored continuously using
a rectal thermometer (Physitemp™, Clifton, NJ). Each rat was
positioned in right lateral recumbency and temporary coronary
ischemia was induced as previously described (Masini et al.,
2003). Following a left 4th intercostal thoracotomy, the heart was
exposed and pericardiectomy was performed. The left auricle was
gently retracted exposing the area of the left anterior descending
coronary artery. Coronary ischemia was induced (group 1, 2) and
maintained for 30min by encircling the left anterior descending
(LAD) branch of the left coronary artery, 1–3mm from the tip
of the normally positioned left auricle, with 6–0 silk suture with
a tapered needle (Sofsilk™, Covidien, Norwalk, CT). The suture
was tightened over a 2mm section of PE-50 tubing to prevent
vascular injury and to permit the release of the ligature during
the reperfusion period. After release of the suture, reperfusion
was allowed to occur for 60min. Reperfusion of the previously
occluded coronary artery was confirmed by visual inspection.
ECHOCARDIOGRAPHY
Left ventricular function was assessed with two-dimensional and
M-mode echocardiography (Hagar et al., 1995). Images of the
left ventricle (LV) were obtained at three different time points:
after exposing the heart but prior to ligation; at the end of the
ischemic period; and at the end of the reperfusion period. Before
each echocardiographic measurement, saline was infused into the
left hemithorax to minimize air artifacts and the hemithorax was
temporarily closed using 4–0 Nylon suture (Ethicon, Johnson
and Johnson, New Brunswick, New Jersey). Heart function was
assessed by echocardiography at three different time points: prior
to ischemia (baseline), after 30min of LAD ligation (end of
ischemia), and at 1 h post reperfusion (end of reperfusion) using
an ultrasound unit (Vivid7™, GE Medical Systems, Milwaukee,
WI, USA) equipped with a 13-MHz linear phase arrayed trans-
ducer (GE i13L) and proprietary software for rodent imaging.
Acquisition frame rates were 159/s. The heart was first imaged
with 2D echocardiography using a short axis-imaging plane at
the level of the papillary muscles. The M-mode cursor was then
placed perpendicular to the ventricular septum and LV poste-
rior wall to acquire M-mode imaging of the LV. Images were
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stored in digital format on a magnetic optical disk for subsequent
review and analysis. Measurements of the LV internal diameter
at end- diastole (LVIDd) were taken at the time of maximal LV
diastolic dimension, whereas measurements of the LV internal
diameter at end-systole (LVIDs) were taken at the time of the
apogee of the systolic excursion of the posterior wall. Five differ-
ent measurements were taken and the average number was used
as a single data point for statistical analysis. Left ventricular frac-
tional shortening (FS) was calculated by the formula: FS (%) =
(LVIDd-LVIDs / LVIDd) × 100. Fractional area shortening (FAS)
was calculated by tracing the endocardial border at the maximal
LV diastolic diameter, and minimal LV systolic diameter. FAS was
calculated by the formula FAS (%) = (LVAd-LVAs/LVAd) × 100.
TISSUE SAMPLING
Before termination of the experiment, the LAD was re-occluded
and 1mL of 1% Evans blue solution (Sigma-Aldrich, St. Loius,
MO) was perfused in a retrograde manner with a 22-gauge nee-
dle inserted into the ascending aorta (group 1, 2) to identify
the area at risk of infarction. The heart was then removed and
placed in a rodent slicer matrix (Zivic instruments, Pittsburgh,
PA) and cooled in a −80◦C freezer for 10–15min to facilitate
slicing. After freezing, 5–6 heart sections of 2mm thickness were
made. Sections of the ventricles from the level of the ligature to
the apex were then incubated in 2% triphenyltetrazolium chlo-
ride (TTC; Sigma-Aldrich, St. Louis, MO) solution in a 37◦C
bath for 20min to visualize the unstained infarcted region. After
TTC staining, viable myocardium stains brick red and the infarct
appears pale white. This staining technique relies on the ability
of dehydrogenase enzymes in viable myocytes to convert the stain
to a brick red color. Heart slices were placed in buffered formalin
and infarct size analysis of the third most distal heart slice (from
apex-to base) was performed after 24 h.
DETERMINATION OF INFARCT AREA
Infarct area was identified using tetrazolium chloride as a vital
staining technique (Fishbein et al., 1981; Ytrehus et al., 1994).
Digital images were made of the apical side of the third slice
of the heart from the apex. The area of infarction and LV areas
at risk were determined by computerized planimetry using an
image analysis software program (Image/J, National Institutes of
Health). Area at risk for infarction was defined using Evan’s blue
dye that was injected during LAD occlusion at the termination
of the experiment. Within the area at risk, the infarct area was
identified by a pale region in the absence of red TTC staining and
was expressed as a percentage (infarct area /area at risk × 100).
Measurements were repeated 5 times for each heart and the aver-
age of these 5 measurements was used to calculate area at risk
and infarct area. The individual conducting the measurements
was blinded to the experimental group.
STATISTICAL ANALYSIS
Statistical calculations were performed using a computer soft-
ware program (Statview, SAS Institute, Inc, Cary, NC). Data were
tested for distribution and equality of variance. Data for each time
period and treatment group were summarized and are reported
as means ± SD. Fractional shortening (FS%) and FAS were com-
pared over the 3 different time periods and between treatment
groups, using a two-way ANOVA for repeated measures (with
time period as the within-groups and treatment as the between-
subjects factors). Comparison of infarct size% between the two
treatment groups was made explored using Student’s t-test for
unpaired data. A p < 0.05 was considered statistically significant.
RESULTS
BILIRUBIN PRETREATMENT SIGNIFICANTLY REDUCED RELATIVE
INFARCT SIZE AFTER LAD OCCLUSION AND 1H OF REPERFUSION
Successful coronary artery occlusion was confirmed in each ani-
mal by visual examination of myocardial pallor, by echocar-
diographic identification of real-time, segmental wall motion
abnormalities, and quantitatively by vital staining. Left anterior
descending artery occlusion consistently created a large area at
risk, as shown by delineation using Evans blue dye (non-ischemic
zone) (Figure 1). Staining with TTC delineated the infarct site
in the transverse heart section (third section from apex), with
the area of infarction appearing pale, and the area at risk in red
(Figure 1). Mean infarct size reported as a percentage of the area
at risk in the non-treated rats was 25.51% ± 4.9 whereas the
mean infarct size in the treated bilirubin group was 13.34%± 5.7.
Infarct size was significantly smaller in the bilirubin treated group
when compared to the non-treated group (p = 0.0067, Figure 1).
BILIRUBIN SUPPLEMENTATION HAD MINIMAL EFFECTS ON CARDIAC
FUNCTION IN THE ACUTE REPERFUSION PERIOD
Left ventricular systolic function was profoundly decreased in
both experimental groups after IR, with segmental LV wall dys-
function and resulting decreases in FS% (Figure 2) and AS%
(Figure 3). LV function as estimated by FS% was less depressed
during the period of ischemia in BR-treated rats, when com-
pared to control (vehicle treated) rats (p = 0.034). However, no
significant difference in measurements of LV function remained
at the time of reperfusion (Figure 4). Left ventricular function
was relatively unchanged throughout the anesthetic period in
sham rats, validating the model and echocardiographic tech-
nique. For FAS, LV function decreased significantly in both exper-
imental groups after IR. Although FAS showed a similar trend
toward improvement in the bilirubin group during the time of
ischemia (Figure 5), differences from control were not statistically
significant (p = 0.098). Furthermore, there was no significant
difference in measurements of LV, FAS at the time of reperfusion.
DISCUSSION
Results of this study showed that bilirubin pre-treatment sig-
nificantly reduced infarct size in a rodent model of acute LAD
occlusion and 1 h reperfusion. Mean infarct size was nearly 50%
less in the treated group when compared to untreated controls.
These results correlate with the protective effect seen after phar-
macologic or genetic upregulation of HO-1 prior to tissue injury
(Yet et al., 2001; Melo et al., 2002; Tullius et al., 2002; Vulapalli
et al., 2002) and suggest that bilirubin therapy may offer a sim-
ple pharmacologic means to substitute for the effects of HO-1
upregulation in a safe and readily achievable manner. Although
high doses of bilirubin are potentially toxic in neonates (Scheidt
et al., 1977; Laws, 1978; Hansen, 1993), the doses used in our cur-
rent study are designed to produce serum concentrations that are
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FIGURE 1 | Bilirubin significantly decreases infarct area after LAD
occlusion. Myocardial infarction associated with 30min ischemia and 1 h
reperfusion was documented using TTC staining. Mean infarct size is
reported as a percentage of the area at risk (infarct area %) in the control
rats and in rats that received 20 uM/kg IP bilirubin treatment 1 h before
ligation of the LAD (A). While there was considerable variation among rats,
as a group, infarct area % for bilirubin treated rats was significantly smaller
in the bilirubin treated group when compared to the non-treated group
(∗p = 0.0067). Representative image of TTC stained heart slices are
arranged from apex (left) to heart base (right) for control (B) and bilirubin
treated rats (C). Infarct size was quantitated using intravital staining with
Triphenyltetrazolium chloride (TCC) in the third heart slice from the apex (in
rectangular box). Active dehydrogenases in viable myocardial cells convert
the water-soluble compound into a brick-red, insoluble precipitate; in
contrast, the infarct area in this image is pale-white. Evan’s blue staining
was used to identify the area that was unaffected by the ligation, with the
remaining area representing the area at risk.
within the physiologic range in humans (5–20µM; Sies and Stahl,
1995) and would not be expected to incur any risk in a healthy
adult. IP administration of bilirubin has been shown to increase
plasma levels of bilirubin, reaching a peak at approximately 1 h
after administration (Wang et al., 2006). Bilirubin is then quickly
eliminated from the circulation and redosing or chemical modi-
fication of the molecule would be necessary to create a sustained
effect. In type 2 Crigler-Najjar syndrome individuals the level of
bilirubin maintain at 19mg/dL for 50 years without detectable
damage to the nervous system (Gollan et al., 1975). Hence, in
our study dosages between 3 and 20mg/kg have been used to
increase total serum bilirubin concentrations into the physiologic
range (0.5 to 1mg/dL) and to achieve physiologic effects in rodent
FIGURE 2 | Fractional shortening was decreased in all groups after LAD
occlusion. Two-dimensional imaging of the LV at the level of the papillary
muscles was obtained. The anatomical M-mode cursor (green line) was
then placed perpendicular to the ventricular septum and LV posterior wall to
acquire M-mode imaging of the LV as indicated in the image (top).
Representative images of rats in the control (A) and bilirubin treated group
(B) show segmental hypokinesis secondary to myocardial ischemia and
severely reduced systolic function at the time of reperfusion (FS 11 and
21%, respectively), while systolic function was normal for sham rats (C) at
the equivalent time period (FS 44%).
models (Wang et al., 2004, 2006; Lanone et al., 2005; Kirkby
et al., 2007). Preconditioning therapies are typically most effec-
tive when initiated prior to the onset of tissue injury. Although
bilirubin had significant protective effects in this model, treat-
ment 1-h before myocardial infarction would be impractical as
a clinical treatment of human myocardial infarction. However, in
elective situations where ischemia might be predicted, as with an
interventional coronary procedure, pretreatment with bilirubin
could be a potential option. Future studies will investigate the
efficacy of bilirubin administration during ischemia, but prior
to reperfusion- a dosing protocol that would be more clini-
cally applicable. Moreover, in the serum, ∼99% of bilirubin is
bound to plasma protein and hence unavailable for intracel-
lular actions (Sedlak and Snyder, 2004). Alternatively, creation
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FIGURE 3 | Determination of area shortening. Baseline measurements of
the LV internal area at end-diastole (LVAd) (A) and at end-systole (LVAs) (B)
were obtained in a control rat prior to ischemia. Fractional area shortening
was calculated using the formula: (LVAd-LVAs/LVAd) × 100. Repeat images
show alterations in LVAd and LVAs for a control rat (C,D) and bilirubin
treated rat (E,F) after 30min of ischemia. Note the severely decreased area
shortening % that occurred after LAD occlusion and the segmental
hypokinesis in the area of myocardial injury (white arrows) in both groups.
of targeted drugs that can produce more sustained increases in
serum bilirubin concentration by releasing it from the binding
sites in the serum proteins may facilitate prophylactic treatment
of individuals that are at risk ofmyocardial infarction. Limitations
in group size restricted our ability tomeasure function and infarct
size at multiple time points after injury in this initial study. In
addition, lack of a control group that received bilirubin alone
(without LAD occlusion) makes us unable to discern whether
bilirubin has direct effects on LV function in the healthy animal.
FIGURE 4 | Bilirubin improves fractional shortening at the end of
ischemia. Mean (s.e.m.) fractional shortening measurements obtained by
echocardiography of sham (non-ischemic), control (ischemia + vehicle) and
control (ischemia + 20 uM bilirubin IP 1 h before induction) groups at
baseline, at the end of 30min of ischemia and 1 h after reperfusion. Left
ventricular function remained relatively constant throughout the anesthetic
period in the sham group while ischemia caused significant decreases in
fractional shortening in both control and bilirubin treated rats. LV systolic
function was higher in the bilirubin-treated group during ischemia, but this
effect was not evident after reperfusion. ∗p < 0.05 vs. control, †p < 0.05
vs. sham.
Based on the positive effects seen in this initial study, future exper-
iments involving additional control groups and recovery models
are indicated.
A variety of methods are available for measurement of infarct
size, although vital staining techniques are considered the stan-
dard method (Fishbein et al., 1981; Ytrehus et al., 1994). TTC is
typically used to stain viable tissue where active dehydrogenases
in myocardial cells convert the water- soluble compound into a
brick-red, insoluble precipitate. Tetrazolium chloride staining is a
well-validated method that allows the early detection of myocar-
dial infarction (Fishbein et al., 1981; Ytrehus et al., 1994). Tissue
lacking hydrogenase enzyme activity is either dead or destined to
die. It should be noted however, that tissue that stains positive
is not necessarily healthy and injury may progress for hours or
even days after reperfusion. The longer the reperfusion period,
the more reliable the staining method becomes for discriminat-
ing between dead and viable tissue. While some researchers state
that reperfusion times of less than 3 h (2 h for perfused hearts)
canmake this technique less reliable (Fishbein et al., 1981; Ytrehus
et al., 1994), others report that the technique can be used reliably
after 1 h of reperfusion (Clark et al., 2000; Masini et al., 2003).
Our results showed minimal differences in echocardiographic
function at the time of reperfusion despite a clear decrease in
infarct size in the bilirubin pretreated group. Themarked decrease
in cardiac function seen in both control and bilirubin treated
hearts is likely due to a phenomenon termed myocardial stun-
ning. Reversibly damaged myocytes do not contract as efficiently
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FIGURE 5 | Bilirubin shows no detectable effect on area shortening.
Fractional area shortening was calculated as an additional measure of global
left ventricular function in sham (non-ischemic), control (ischemia + vehicle)
and control (ischemia + 20 uM bilirubin IP 1 h before induction) groups at
baseline, at the end of 30min of ischemia and 1 h after reperfusion. Similar
to results for fractional shortening, LAD occlusion caused significant
decreases in FAS in both control and bilirubin treated rats. Bilirubin treated
rats showed a trend toward better LV systolic function at the end of
ischemia, but the difference was not statistically significant (p = 0.098).
†p < 0.05 vs. sham.
FIGURE 6 | Proposed Model of lipophilic bilirubin inhibition of
peroxidase activity of cyt c, lipid (cardiolipin) oxidation, and apoptosis
in cardiomyocytes.
as they did in the control state. Myocardial stunning is a reversible
reduction in cardiac function that is not accounted for by tis-
sue damage; rather, ischemia results in conversion to anaerobic
glycolysis and lactate accumulation with eventual cessation of
contraction in the entire area at risk persists for hours or days.
It has been shown that myocytes reperfused late in the reversible
phase of ischemia still exhibit stunning 48–72 h after being reper-
fused and that this phenomenon is due to free radical induced
injury (Bolli, 1990, 1992). This reverse phenomenon would not
have been encountered in our acute model. In some circum-
stances, myocardial stunning can be ameliorated if free radical
scavengers are given immediately before reperfusion (Bolli, 1988).
We elected to use transthoracic echocardiography to estimate
systolic LV function. Echocardiographic measurements of FS%
and FAS% are well established as methods for estimation of
global function. However, both of these indices may be subop-
timal for assessing regional wall motion abnormalities typical
of focal myocardial ischemia. Both FS and FAS are intended to
estimate ejection fraction of a symmetrically contracting ven-
tricle. While FAS did identify wall motion abnormalities in real
time, the quantitation of these was likely attenuated by con-
sidering contraction of the entire ventricle or the single line
method of the M-mode study, which may not effectively rep-
resent segmental function. Physicians typically score regional
wall motion abnormalities in ischemic patients when evaluat-
ing 2D echocardiograms; however, these scores are subjective
and at best semiquantitative. We attempted to apply myocar-
dial strain imaging in these studies, but were disappointed by
the reproducibility in pilot studies and did not include these
methods in the current report. However, with refinements in
transducers and algorithms, this approach would seem feasi-
ble in future studies. The use of strain might also mitigate the
impact of tethering, wherein adjacent segments can affect the
motion of each region leading to either over-representation or
under-representation of the true segmental wall motion abnor-
malities. Lastly, ischemia also can affect ventricular diastolic
function regionally and globally, but this was not evaluated in
these rats.
Due to the invasive nature of this study, all measurements were
obtained with the rats under general anesthesia maintained with
isoflurane. It is known from previous rodent studies that the dose
and type of anesthetic may influence heart rate, LV systolic and
diastolic function, LV thickness and LV cavity dimensions. When
comparing isoflurane (ISF) and ketamine to pentobarbital used
as anesthetic agents, isoflurane and ketamine yielded echocar-
diographic LV structural and functional data different to those
obtained in conscious rats, with isoflurane anesthesia resulting
in significantly lower FS and AS% as compared with other anes-
thetic agents (Plante et al., 2006; Stein et al., 2007; Droogmans
et al., 2008; Jakobsen et al., 2010). Although general anesthesia
is likely to have affected cardiac functional parameters in our
model, measurements of LV function (FS and FAS%) remained
constant throughout the anesthetic period in sham-operated rats,
validating the model and echocardiographic technique.
In rat, it has been demonstrated that protective effects of
bilirubin rinses on liver for tissue grafts by reducing hepa-
tocellular oxidative damages, post-tranplantational reperfusion
injuries, and transplanted organ dysfunction (Kato et al., 2003).
Our results demonstrate that bilirubin has cardiac protec-
tive effect against IR injuries/oxidative damages. However, the
protective action of rinse of bilirubin on post-tranplantation
reperfusion injury and organ dysfunction in the heart remains
to be explored. Our in vivo promising results show that there
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is a potential opportunity for the bilirubin rinses for protection
against post-tranplantational reperfusion injury and transplanted
graft dysfunction in cardiac tissues. This simple costless proce-
dure could be of greater advantage for the heart transplant.
Based on our studies and reported literature, we propose
that antioxidant bilirubin inhibits the peroxidase activity of
cytochrome c, oxidation of lipids (cardiolipin), and apoptosis in
cardiomyocytes as depicted in Figure 6. It has been reported that
oxidative stress or damage is increased in heart disease patients
and during surgical reperfusion of the whole heart (Ferrari et al.,
1998; Tomaselli and Barth, 2010). Oxidative stress is associated
with increased formation of ROS. The level of ROS is increased
under ischemia and greatly accelerated with the sudden rein-
troduction of oxygen at the onset of reperfusion (Zweier and
Talukder, 2006). The increased production of ROS leads to oxida-
tive damage of various biomolecules and lipids. In heart, apop-
tosis increases during IR (Dispersyn and Borgers, 2001; Cheng
et al., 2010). Mitochondria are now recognized to play a crit-
ical role in mediating both apoptotic and necrotic cell death.
In the mitochondrial inner membrane, cardiolipin (CL) is an
acidic phospholipid confers fluidity and stability on the mem-
brane (Orrenius and Zhivotovsky, 2005; Gonzalvez and Gottlieb,
2007). Cytochrome c (cyt c) is anchored to the mitochondrial
membrane through both hydrophobic and electrostatic inter-
actions with CL and form CL-cyt c complex (Orrenius and
Zhivotovsky, 2005; Gonzalvez and Gottlieb, 2007). The release
of cyt c from the mitochondria is an early step in apoptosis
(Kluck et al., 1997). The peroxidase activity and oxidation of
cyt c and CL respectively increases during apoptosis (Velayutham
et al., 2011). The oxidized CL facilitates the release of cyt c from
mitochondria during apoptosis. Studies have shown that physi-
ological role of bilirubin is an endogenous antioxidant (Sedlak
and Snyder, 2004; Sedlak et al., 2009). Bilirubin has cytopro-
tective effects against reactive oxygen species and lipid radicals
(Sedlak et al., 2009). Bilirubin is hydrophobic and its antioxi-
dant effect exceeds that of vitamin E toward lipid peroxidation
(Stocker et al., 1987). It is well documented that bilirubin pre-
vents oxidative degradation of lipids and improves cell survival
(Sedlak et al., 2009). In men, it has been demonstrated that
inverse relationship between serum bilirubin and atherosclerosis
(Novotný and Vítek, 2003). In our study the administration of
bilirubin decreased the infarct size in the heart during ischemia.
This in vivo result suggests that lipid soluble bilirubin could
prevent the oxidation of lipids such as cardiolipin and regu-
late apoptotic cell death and decreases infarct size in the heart
during IR.
In conclusion, bilirubin supplementation was found to sig-
nificantly reduce infarct area in an LAD occlusion model of
myocardial IR injury. Minimal improvements were noted in
LV function in the early reperfusion period. Current evidence
suggests that administration of bilirubin may provide an effec-
tive means of pre-conditioning prior to elective procedures
or graft involving cardiac IR injuries. Conceivably, adminis-
tration of drugs to release bilirubin from the binding sites
in serum proteins is an alternate method of treatment for
the protection of individuals that are at risk of myocardial
infarction.
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